RYBREVANT® plus LAZCLUZE™ by Johnson & Johnson got approved by the U.S. FDA as a first-line chemotherapy-free treatment for patients with EGFR-mutated advanced lung cancer. LAZCLUZE™ is anti-cancer drug developed by Yuhan Corporation licensed out to Janssen Biotech in 2018.
Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) approved RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved […]
Business Development Manager Position Available
We’re #hiring. Know anyone who might be interested? Please feel free to share this information with others who may be interested.
Yuhan USA team attended NEBS 2024 32nd Annual Conference
Yuhan USA team attended NEBS 2024 32nd Annual Conference on May 18th at the Harvad Medical School. Yuhan is a proud sponsor of NEBS and it’s always great to connect with such a talented group of scientists. Special congratulations to Dr. Won-Seok Lee for receiving NEBS-Yuhan award! His work on “Cells with intranuclear Huntingtin aggregates have long (>150) somatic CAG-repeat […]
Yuhan USA to participate at 2024 BIO International Convention in June
Yuhan USA to participate at 2024 BIO International Convention in June Yuhan USA, a subsidiary of Yuhan Corporation, will be participating in 2024 BIO International Convention on June 3-6 (San Diego, CA). Yuhan USA is looking for potential therapeutic assets with validated proof-of-concept data for in-licensing. The company’s R&D focus areas are Oncology (targeted therapy, […]
Yuhan Corporation’s ‘IgE Trap; YH35324’ Surpasses ‘Xolair’ in Phase 1 Trials, Delivering Superior IgE Suppression in High IgE Patients (biospectator.com)
Yuhan Corporation’s ‘IgE Trap; YH35324’ Surpasses ‘Xolair’ in Phase 1 Trials, Delivering Superior IgE Suppression in High IgE Patients YH35324 is an Fc fusion protein of the IgE series, ‘IgE Trap’, which is a form that fuses the extracellular domain of the IgE receptor (FcεR1) with a hybrid Fc. Its main mechanism of action is […]
‘Amivantamab’ and ‘Lazertinib’ Combination Treatment Shows Extended PFS as First-line of Therapy in NSCLC
Yuhan Corporation’s 3rd generation EGFR TKI, ‘Lazertinib’, has taken another step towards its global blockbuster aspirations.This achievement comes as a result of successful outcomes in the clinical trial named ‘MARIPOSA,’ in which Janssen evaluated the anti-cancer drug ‘Amivantamab’ in combination with ‘Lazertinib’ compared to AstraZeneca’s ‘Osimertinib’. According to industry reports on October 2nd, Janssen, a […]
Yuhan and Cyrus Therapeutics signed an agreement for Joint Research on Anti-Cancer Target Therapeutics
Yuhan announced that it has signed an MOU with Cyrus Therapeutics to develop a small molecule anti-cancer target therapy. Cyrus Therapeutics is a Korean biotechnology company with small molecule therapeutics and targeted proteolysis (TPD) technology that degrades protein and removes cancer cells. Through the agreement, the two companies plan to cooperate in the fields of […]
Yuhan Corporation Announces Free Supply of Its New Lung Cancer Drug “Lazertinib” Until Covered by Insurance through Expanded Access Program (EAP) in South Korea
Yuhan Corporation, a leading pharmaceutical company, has announced that it will provide its newly developed drug, “Lazertinib,” as a first-line treatment for free until it is covered by health insurance in South Korea. This initiative is in line with the company’s commitment to giving back to society, a value that was cherished by its late […]
Business Development Manager Position Opening
Yuhan USA Corporation– 유한양행 미국 법인 Work locations: San Diego, CA or Boston, MA Employee type: Full-time Visa Sponsorship available: No Contact Information: info@yuhan-usa.com 유한USA는 96년의 전통을 가진 한국 최대 제약회사 중 하나인 유한양행의 미국 법인으로 유한양행이 글로벌 제약사로 발돋움 하기 위한 세계화 전략의 전초기지로서 사업 개발 및 신약 개발 협업의 기회를 함께할 인재를 찾고 […]
Yuhan Corporation confirms efficacy of Lazertinib, a new drug for NSCLC in Phase 3 trial
The top line results for the phase 3 clinical trial of the 3rd generation EGFR TKI ‘Lazertinib’ being developed by Yuhan Corporation have been announced. The results confirmed the efficacy of Lazertinib as a first-line treatment and Yuhan Corporation plans to submit an application for approval to expand indications in South Korea in Q1 of […]